Dr Julie Decock holds a Master in Biomedical Sciences from the Free University of Brussels (VUB), Belgium. She was awarded a Ph.D. in Medical Sciences in 2003 from the Catholic University of Leuven (KULeuven), Belgium. Her PhD dissertation focused on the clinical utility of tumor and circulating proteases as novel biomarkers for breast cancer. During her PhD, she co-founded the breast cancer biobank at the University Hospital of Leuven, Belgium. Dr Decock undertook a postdoctoral position at the University of East Anglia (UEA), UK where she studied the role of several protease families in breast, prostate and pancreatic cancer using in vitro and in vivo models. She joined QBRI in 2013 as a postdoctoral researcher and was promoted to scientist in 2016. In addition, she holds an assistant professor position at the College of Science and Engineering of the Hamad Bin Khalifa University. Dr Decock has 25 peer-reviewed scientific articles with over 760 citations and has an h-index of 15. She is a member of the editorial board of Frontiers in Oncology and the Journal of Translational Medicine. She serves on various grant review boards, nationally and internationally.
Dr Decock’s research interest lies in the tumor microenvironment and how its constituents together with tumor antigens can be exploited as prognostic biomarkers and/or therapeutic targets for immunotherapy. She also has an interest in the molecular mechanisms by which tumor-associated Cancer Testis Antigens drive/support tumorigenesis and/or neoplastic progression. Her research group is focused on breast cancer, in particular triple negative breast cancer.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J*. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol 2018 (In Press). doi: 10.3389/fimmu.2018.00947. Review.
Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, Quinn C, Jithesh P, Syed N, Al Bader SBJ, Bedri S, Wang E, Marincola FM, Chaussabel D, Kuppen P, Miller LD, Bedognetti D, Hendrickx W. A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Res. 2017 Mar 20;6:296. doi: 10.12688/f1000research.10960.2.
Decock J*, Hendrickx W, Thirkettle S, Gutiérrez-Fernández A, Robinson SD, Edwards DR. (2015). Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. Breast Cancer Res 17:38.
Thirkettle S, Decock J, Arnold H, Pennington CJ, Jaworski DM, Edwards DR. (2013). Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. J Biol Chem 288(23):16282-94.
* corresponding author
For a complete list of publications, go to PubMed